Matrix metalloproteinases and atherosclerotic plaque instability
- 1 June 2002
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 89 (6) , 680-694
- https://doi.org/10.1046/j.1365-2168.2002.02099.x
Abstract
Background: There is growing interest in the role of matrix metalloproteinases in atherosclerosis. Excessive tissue remodelling and increased matrix metalloproteinase activity have been demonstrated during atherosclerotic plaque disruption, a frequent predeterminant of ischaemic cardiac events and stroke. These enzymes represent a potential target for therapeutic intervention to modify vascular pathology.Methods: The core of this review is derived from a Medline database literature search.Results: There is convincing evidence of increased matrix metalloproteinase activity during acute plaque disruption. Evidence for an imbalance promoting increased matrix degradation is less well documented. However, studies of matrix metalloproteinase inhibition in models of vascular disease suggest a potential therapeutic benefit.Conclusion: In vivo studies of matrix metalloproteinase inhibition are required to study the potential for reversal or deceleration of the excessive tissue remodelling that accompanies acute plaque disruption.Keywords
This publication has 99 references indexed in Scilit:
- Expression of Collagenase-3 (MMP-13) in Human Abdominal Aortic Aneurysms and Vascular Smooth Muscle Cells in CultureBiochemical and Biophysical Research Communications, 1999
- Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancerEuropean Journal Of Cancer, 1996
- In Situ Localization and Quantification of mRNA for 92-kD Type IV Collagenase and Its Inhibitor in Aneurysmal, Occlusive, and Normal AortaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Pathogenesis of atherosclerosisand the role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitorsThe American Journal of Cardiology, 1995
- Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis.Heart, 1995
- The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancerSurgical Oncology, 1995
- Doxycycline and Chemically Modified Tetracyclines Inhibit Gelatinase A (MMP‐2) Gene Expression in Human Skin KeratinocytesAnnals of the New York Academy of Sciences, 1994
- A Sequence-Tagged Site Map of Human Chromosome 11Genomics, 1993
- Inhibition of human collagenases by sulfur-based substrate analogsBiochemical and Biophysical Research Communications, 1991
- Rheumatoid ArthritisNew England Journal of Medicine, 1990